Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review
Journal of Clinical Medicine · 25.07.2026 · 15 (15) · 5832
DOI: 10.3390/jcm15155832 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.07.2026. Verfasst von Ameen Nasser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy associated with substantial morbidity and mortality. This systematic review evaluates the effects of tafamidis on echocardiographic parameters, cardiac biomarkers, functional outcomes, mortality, and safety in patients with ATTR-CM.
Methods
This systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261391553). PubMed, Embase, and Web of Science were searched through 20 March 2026. Eligible studies included adults with ATTR-CM treated with tafamidis and reporting, echocardiographic, biomarker, functional, mortality, or safety outcomes. Randomized controlled trials and observational studies were included. Risk of bias was assessed using the Cochrane RoB 2 tool and Newcastle–Ottawa Scale. Due to substantial heterogeneity, a narrative synthesis was performed.
Results
Seventeen studies were included with a total of 1890 patients. Tafamidis treatment was potentially associated with stabilization of global longitudinal strain, preservation of functional status, and lower all-cause mortality compared with untreated or control cohorts. Biomarker findings, including N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT), were heterogeneous and did not demonstrate a consistent pattern of improvement. Functional outcomes, including New York Heart Association (NYHA) class, 6-minute walk distance (6MWT), National Amyloidosis Center (NAC) staging, and quality-of-life measures, suggested slower clinical deterioration among treated patients. Limited available safety data indicated that tafamidis was generally well tolerated, with no major safety concerns identified.
Conclusions
Current evidence may suggest that tafamidis slows disease progression and may potentially be associated with improved survival in ATTR-CM. Further prospective studies with standardized outcome reporting are needed. Evidence was limited by heterogeneity in study design, outcome reporting, and follow-up duration, with most included studies being observational.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Innovative Medical Education, Jagiellonian University Medical College, 30-688 Krakow, Poland.
- Center for Invasive Cardiology, Electrotherapy and Angiology, 33-300 Nowy Sacz, Poland.
ORCID-Profile: Ameen Nasser, Mateusz Michalczak, Wiktoria Małgorzata Zgoda, Anna Żądło, Tomasz Tokarek
Zitieren
APA
Nasser, A., Michalczak, M., Malkowski, A., Zgoda, W. M., Michalczak, J., Żądło, A., & Tokarek, T. (2026). Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review. Journal of Clinical Medicine, 15(15), 5832. https://doi.org/10.3390/jcm15155832
Vancouver
Nasser A, Michalczak M, Malkowski A, Zgoda WM, Michalczak J, Żądło A, et al. Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review. Journal of Clinical Medicine. 2026;15(15):5832. doi:10.3390/jcm15155832
BibTeX
@article{Nasser2026,
author = {Nasser, Ameen and Michalczak, Mateusz and Malkowski, Alexandra and Zgoda, Wiktoria Małgorzata and Michalczak, Jakub and Żądło, Anna and Tokarek, Tomasz},
title = {Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {15},
pages = {5832},
doi = {10.3390/jcm15155832}
}
EUVIMED